Poging GOUD - Vrij
“We aim to make molecular diagnostics based on RT-PCR technology mainstream in India”
Bio Spectrum
|September 2020
Backed by Serum Institute of India, Pune based startup Mylab Discovery Solutions is aggressively launching new products in the diagnostic testing space to overcome the challenges posed by the pandemic. After raising funds from the Department of Biotechnology (DBT) and few private investors, the Mylab team has recently developed a fully-automated sample to-PCR-ready system for molecular diagnostics, which is a first in India. Founded in 2016, it is the first company in Asia and second company worldwide to develop and manufacture FDA approved ID-NAT kits for accurate detection of HIV, HBV, HCV and other infections. BioSpectrum India got in touch with Hasmukh Rawal, Managing Director, Mylab Discovery Solutions to find out more about the initiatives being taken up by the startup to combat COVID-19. Edited excerpts;
Hasmukh Rawal, Managing Director, Mylab Discovery Solutions, Pune
What are the key advantages being offered by the Compact XL system compared to the conventional RT-PCR testing systems?
Compact XL is a sample-to-PCR ready machine for molecular diagnostics that eliminates the huge infrastructure cost of setting up a molecular lab. It is designed to automate lab operations from sample handing to RT-PCR tube preparation. It has flexibility to test multiple parameters with multiple samples at the same time, a never before the feature. With 32 separate channels, dual-deck facility, automated barcode reading, auto fed protocol, self-sanitization, and laboratory information management system (LIMS) connectivity defines Compact XL, as a complete walk-away system. It is a cartridge-based machine and can test multiple samples concurrently. It can be used for a wide range of RNA/DNA-based tests including COVID-19 RT-PCR tests. The machine can take a variety of sample types such as plasma, tissue, sputum, and swab. Other benefits include: Save on real estate costs- no need for multiple rooms and 1000+ sq ft of space. Compact XL reduces footprint to a single room of 100 sqft; Reduced manpower- a traditional lab needs 3-4 skilled molecular biologists. Compact XL allows you to run a lab with just 1 technician; Less Equipment & Consumables- significantly cost-saving on dozens of small equipment and consumables, made obsolete by Compact XL; Zero Manual Error- an automated process with no manual intervention. Accurate material handling and process adherence for reliable results; Low maintenance- Compact XL is a hassle and maintenance free system to save you costs in short and long term. To make India self-reliant in advanced diagnostics, Compact XL is our most ambitious project to date.
Dit verhaal komt uit de September 2020-editie van Bio Spectrum.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Bio Spectrum
Bio Spectrum
MAHE teams up with OpenAI to integrate AI to enhance outcomes
Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University in Karnataka, has partnered with OpenAI to integrate advanced artificial intelligence (AI) tools across teaching, research, and academic administration.
1 min
April 2026
Bio Spectrum
Jubilant Bhartia Foundation & McGill University to launch CoE in AI education
The Jubilant Bhartia Foundation in collaboration with McGill University (Canada), has signed a Memorandum of Understanding (MoU) to create the Centre of Excellence (CoE) in artificial intelligence (AI) Education and Research.
1 min
April 2026
Bio Spectrum
Heeding Auditory Warning Signs
By 2050, nearly 2.5 billion people are projected to have some degree of hearing loss, and more than 700 million might require hearing rehabilitation. That's according to the World Health Organization (WHO).
2 mins
April 2026
Bio Spectrum
Botanic Healthcare on-boards Narahari Naidu as Group Chief Financial Officer
Secundarabad-based Botanic Healthcare, a globally leading nutraceutical company, has announced the appointment of Narahari Naidu as its Group Chief Financial Officer (CFO).
1 min
April 2026
Bio Spectrum
Paras Health ropes in Balkishan Sharma as Group CHRO and Business Transformation Officer
Paras Health has announced the appointment of Balkishan Sharma as Group Chief Human Resources Officer (Group CHRO) and Business Transformation Officer.
1 min
April 2026
Bio Spectrum
Parse Biosciences unveils Evercode Whole Transcriptome V4 with shorter workflow
Parse Biosciences, a Qiagen company, has announced the launch of the new Evercode Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers
1 min
April 2026
Bio Spectrum
UK deploys new bone scanners to help prevent fractures
Tens of thousands of patients at risk of osteoporosis and other bone conditions will get faster access to vital bone scans, as 20 new scanners are rolled out across England.
1 min
April 2026
Bio Spectrum
Cytiva expands Fast Trak process development and validation services facility in India
Cytiva, a Danaher company and a leader in the life sciences industry, has inaugurated an expanded facility for Fast Trak process development (PD) and validation services in Bengaluru.
1 min
April 2026
Bio Spectrum
ΑΙ TAKES INDIAN PHARMA REINS
The Indian pharmaceutical sector, one of the largest in the world, is undergoing a strategic transformation in the way it operates. As artificial intelligence (AI) gains prominence across the industry, companies are actively adopting Al-driven solutions to enhance efficiency across the entire pharmaceutical ecosystem. Organisations are investing in AI training programmes to keep their workforce future-ready, foster innovation, strengthen supply chains, and transition away from manual record-keeping. In this industry analysis, experts share their perspectives on how AI is shaping the future of the pharma sector.
10 mins
April 2026
Bio Spectrum
NIH halts arm of clinical trial evaluating potential stroke treatment
The National Institutes of Health (NIH) in the US has stopped an investigational treatment arm of the Comparison of Anti-coagulation and Anti-platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) study, following a regular review by the Data Safety and Monitoring Board (DSMB).
1 min
April 2026
Translate
Change font size
